Northwest Biotherapeutics, Inc. (NWBO)
USD 0.21
(-1.87%)
USD 0.21
(-1.87%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 27.94 Million USD | -10.79% |
| 2022 | 31.32 Million USD | -22.0% |
| 2021 | 40.16 Million USD | 22.07% |
| 2020 | 32.89 Million USD | 260.38% |
| 2019 | 9.12 Million USD | -62.99% |
| 2018 | 24.66 Million USD | -49.56% |
| 2017 | 48.9 Million USD | -7.56% |
| 2016 | 52.9 Million USD | -25.27% |
| 2015 | 70.79 Million USD | 21.14% |
| 2014 | 58.44 Million USD | 211.12% |
| 2013 | 18.78 Million USD | 148.14% |
| 2012 | 7.57 Million USD | 3470.75% |
| 2011 | 212 Thousand USD | -27.89% |
| 2010 | 294 Thousand USD | 185.44% |
| 2009 | 103 Thousand USD | -93.04% |
| 2008 | 1.48 Million USD | -83.0% |
| 2007 | 8.7 Million USD | 1627.38% |
| 2006 | 504 Thousand USD | -20.13% |
| 2005 | 631 Thousand USD | 13.08% |
| 2004 | 558 Thousand USD | -35.94% |
| 2003 | 871 Thousand USD | -88.5% |
| 2002 | 7.57 Million USD | -61.12% |
| 2001 | 19.47 Million USD | 320.7% |
| 2000 | 4.62 Million USD | 83.78% |
| 1999 | 2.51 Million USD | 79.93% |
| 1998 | 1.4 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 28.64 Million USD | 2.51% |
| 2024 Q2 | 28.3 Million USD | -1.47% |
| 2023 Q1 | 32.87 Million USD | 4.94% |
| 2023 Q3 | 31.49 Million USD | 10.74% |
| 2023 Q2 | 28.43 Million USD | -13.49% |
| 2023 Q4 | 27.94 Million USD | -11.27% |
| 2023 FY | 27.94 Million USD | -10.79% |
| 2022 Q4 | 31.32 Million USD | 0.72% |
| 2022 Q3 | 31.09 Million USD | 13.0% |
| 2022 Q1 | 30.65 Million USD | -23.66% |
| 2022 FY | 31.32 Million USD | -22.0% |
| 2022 Q2 | 27.52 Million USD | -10.23% |
| 2021 FY | 40.16 Million USD | 22.07% |
| 2021 Q1 | 32.46 Million USD | -1.33% |
| 2021 Q3 | 28.22 Million USD | -1.9% |
| 2021 Q2 | 28.76 Million USD | -11.38% |
| 2021 Q4 | 40.16 Million USD | 42.31% |
| 2020 Q4 | 32.89 Million USD | 20.89% |
| 2020 FY | 32.89 Million USD | 260.38% |
| 2020 Q3 | 27.21 Million USD | 82.56% |
| 2020 Q2 | 14.9 Million USD | 62.32% |
| 2020 Q1 | 9.18 Million USD | 0.59% |
| 2019 Q2 | 14.7 Million USD | -39.91% |
| 2019 Q1 | 24.47 Million USD | -0.8% |
| 2019 FY | 9.12 Million USD | -62.99% |
| 2019 Q4 | 9.12 Million USD | -10.01% |
| 2019 Q3 | 10.14 Million USD | -31.01% |
| 2018 Q4 | 24.66 Million USD | -46.76% |
| 2018 FY | 24.66 Million USD | -49.56% |
| 2018 Q1 | 49.77 Million USD | 1.78% |
| 2018 Q2 | 48.47 Million USD | -2.62% |
| 2018 Q3 | 46.33 Million USD | -4.42% |
| 2017 Q2 | 47.38 Million USD | -1.92% |
| 2017 Q1 | 48.31 Million USD | -8.68% |
| 2017 FY | 48.9 Million USD | -7.56% |
| 2017 Q4 | 48.9 Million USD | -1.69% |
| 2017 Q3 | 49.74 Million USD | 4.99% |
| 2016 Q2 | 51.6 Million USD | -17.06% |
| 2016 Q1 | 62.22 Million USD | -12.11% |
| 2016 Q3 | 48.94 Million USD | -5.17% |
| 2016 FY | 52.9 Million USD | -25.27% |
| 2016 Q4 | 52.9 Million USD | 8.1% |
| 2015 Q1 | 49.41 Million USD | -15.45% |
| 2015 Q3 | 51.63 Million USD | -19.63% |
| 2015 Q2 | 64.24 Million USD | 30.02% |
| 2015 Q4 | 70.79 Million USD | 37.1% |
| 2015 FY | 70.79 Million USD | 21.14% |
| 2014 Q4 | 58.44 Million USD | 98.82% |
| 2014 Q3 | 29.39 Million USD | 133.73% |
| 2014 Q2 | 12.57 Million USD | 0.51% |
| 2014 Q1 | 12.51 Million USD | -33.39% |
| 2014 FY | 58.44 Million USD | 211.12% |
| 2013 FY | 18.78 Million USD | 148.14% |
| 2013 Q3 | 7.63 Million USD | 213.3% |
| 2013 Q1 | 521 Thousand USD | -93.12% |
| 2013 Q2 | 2.43 Million USD | 367.75% |
| 2013 Q4 | 18.78 Million USD | 146.02% |
| 2012 Q4 | 7.57 Million USD | 1668.69% |
| 2012 Q2 | 1.01 Million USD | 350.44% |
| 2012 FY | 7.57 Million USD | 3470.75% |
| 2012 Q1 | 226 Thousand USD | 6.6% |
| 2012 Q3 | 428 Thousand USD | -57.96% |
| 2011 Q1 | 1.18 Million USD | 302.38% |
| 2011 FY | 212 Thousand USD | -27.89% |
| 2011 Q4 | 212 Thousand USD | -88.8% |
| 2011 Q3 | 1.89 Million USD | -72.26% |
| 2011 Q2 | 6.82 Million USD | 476.92% |
| 2010 Q1 | 139 Thousand USD | 34.95% |
| 2010 Q2 | 436 Thousand USD | 213.67% |
| 2010 Q3 | 286 Thousand USD | -34.4% |
| 2010 Q4 | 294 Thousand USD | 2.8% |
| 2010 FY | 294 Thousand USD | 185.44% |
| 2009 Q4 | 103 Thousand USD | -56.36% |
| 2009 FY | 103 Thousand USD | -93.04% |
| 2009 Q2 | 196 Thousand USD | -88.32% |
| 2009 Q3 | 236 Thousand USD | 20.41% |
| 2009 Q1 | 1.67 Million USD | 13.38% |
| 2008 Q2 | 3.06 Million USD | -12.29% |
| 2008 FY | 1.48 Million USD | -83.0% |
| 2008 Q4 | 1.48 Million USD | -23.67% |
| 2008 Q3 | 1.93 Million USD | -36.82% |
| 2008 Q1 | 3.49 Million USD | -59.81% |
| 2007 FY | 8.7 Million USD | 1627.38% |
| 2007 Q1 | 337 Thousand USD | -33.13% |
| 2007 Q2 | 26.03 Million USD | 7624.93% |
| 2007 Q3 | 17.32 Million USD | -33.44% |
| 2007 Q4 | 8.7 Million USD | -49.75% |
| 2006 Q2 | 2.71 Million USD | -14.1% |
| 2006 Q3 | 861 Thousand USD | -68.3% |
| 2006 Q4 | 504 Thousand USD | -41.46% |
| 2006 FY | 504 Thousand USD | -20.13% |
| 2006 Q1 | 3.16 Million USD | 401.11% |
| 2005 FY | 631 Thousand USD | 13.08% |
| 2005 Q1 | 362 Thousand USD | -35.13% |
| 2005 Q4 | 631 Thousand USD | 17.94% |
| 2005 Q2 | 414 Thousand USD | 14.36% |
| 2005 Q3 | 535 Thousand USD | 29.23% |
| 2004 FY | 558 Thousand USD | -35.94% |
| 2004 Q4 | 558 Thousand USD | 28.57% |
| 2004 Q3 | 434 Thousand USD | -42.67% |
| 2004 Q1 | 709 Thousand USD | -18.6% |
| 2004 Q2 | 757 Thousand USD | 6.77% |
| 2003 Q4 | 871 Thousand USD | -37.11% |
| 2003 Q2 | 2.43 Million USD | -55.45% |
| 2003 Q3 | 1.38 Million USD | -43.1% |
| 2003 Q1 | 5.46 Million USD | -27.85% |
| 2003 FY | 871 Thousand USD | -88.5% |
| 2002 Q1 | 15.6 Million USD | -19.88% |
| 2002 Q2 | 12.02 Million USD | -22.91% |
| 2002 Q3 | 8.53 Million USD | -29.06% |
| 2002 Q4 | 7.57 Million USD | -11.27% |
| 2002 FY | 7.57 Million USD | -61.12% |
| 2001 Q4 | 19.47 Million USD | 108.97% |
| 2001 FY | 19.47 Million USD | 320.7% |
| 2001 Q1 | 18.47 Billion USD | 0.0% |
| 2001 Q3 | 9.32 Million USD | -21.15% |
| 2001 Q2 | 11.82 Million USD | -99.94% |
| 2000 FY | 4.62 Million USD | 83.78% |
| 1999 FY | 2.51 Million USD | 79.93% |
| 1998 FY | 1.4 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -1209596.97% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -1327.033% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -164.772% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -4961.219% |
| Rebus Holdings, Inc. | 5000.00 USD | -558780.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 78.539% |
| Qrons Inc. | 420.00 USD | -6653233.333% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -3526.058% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -5714.919% |
| Skye Bioscience, Inc. | 11.94 Million USD | -134.029% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 28.067% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -287.049% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -36497.952% |
| SQZ Biotechnologies Company | 107.18 Million USD | 73.93% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -1851.353% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -38515.353% |
| Mesoblast Limited | 667.9 Million USD | 95.816% |
| Marizyme, Inc. | 22.01 Million USD | -26.931% |
| Genus plc | 1.02 Billion USD | 97.284% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -1957.197% |
| Pharming Group N.V. | 462.85 Million USD | 93.963% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -743.462% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -5499.562% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -4356.778% |
| ContraFect Corporation | 20.67 Million USD | -35.132% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -7058.41% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -7211.795% |
| IMV Inc. | 31.33 Million USD | 10.818% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -573.995% |
| MultiCell Technologies, Inc. | 126.22 USD | -22139022.168% |
| ONE Bio Corp. | 70.08 Million USD | 60.129% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -2873.75% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 78.255% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -6372.804% |
| Q BioMed Inc. | 3.51 Million USD | -694.876% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 20.566% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -10595.163% |
| Biomind Labs Inc. | 73.81 Thousand USD | -37754.753% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 93.739% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -1828.711% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 6.9% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -917.502% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -3964.665% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -973.45% |
| GB Sciences, Inc. | 103.44 Thousand USD | -26914.172% |
| Alpha Cognition Inc. | 2.45 Million USD | -1039.562% |
| HST Global, Inc. | 1526.00 USD | -1831092.661% |
| CSL Limited | 38.02 Billion USD | 99.927% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -2728.435% |
| Halberd Corporation | 10.13 Thousand USD | -275726.671% |
| Enzolytics Inc. | 361.7 Million USD | 92.274% |
| Agentix Corp. | 261.39 Thousand USD | -10590.457% |
| Resverlogix Corp. | 8.11 Million USD | -244.35% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -1388.061% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.385% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 41.42% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -4268.598% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -122563.623% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -212.253% |
| AVAX Technologies, Inc. | 7.37 Million USD | -278.791% |
| Zenith Capital Corp. | 7410.00 USD | -377012.011% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.175% |
| Ember Therapeutics, Inc. | 184.00 USD | -15186856.522% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -8583.493% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -10591.603% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -2911.333% |
| Kadimastem Ltd | 2.3 Million USD | -1112.805% |
| Helix BioMedix, Inc. | 3.02 Million USD | -823.742% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 46.976% |
| BioStem Technologies, Inc. | 14.56 Million USD | -91.919% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -48843.847% |
| LadRx Corporation | 2.3 Million USD | -1110.807% |
| Cell Source, Inc. | 195.17 Thousand USD | -14217.701% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -7802.335% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -7802.335% |
| NovAccess Global Inc. | 62.24 Thousand USD | -44791.402% |
| Affymax, Inc. | 7.44 Million USD | -275.44% |
| Itoco Inc. | 1.4 Million USD | -1895.897% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -29112.708% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -26262.264% |
| Mobile Lads Corp. | 52.00 USD | -53738361.538% |
| CytoDyn Inc. | 11.13 Million USD | -150.934% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -19445.086% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -156186.353% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -7149.313% |
| SYBLEU INC | 330.46 Thousand USD | -8355.887% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -6725.232% |
| International Stem Cell Corporation | 5.39 Million USD | -418.442% |
| Bioxytran, Inc. | 137.63 Thousand USD | -20202.533% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -86.271% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -68.551% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -35272.152% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -3131.727% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -271.744% |
| Neutra Corp. | 2851.00 USD | -980047.317% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 13.769% |
| PureTech Health plc | 693.97 Million USD | 95.973% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -246.223% |
| IXICO plc | 15.84 Million USD | -76.371% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -237.406% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 72.955% |
| CSL Limited | 38.02 Billion USD | 99.927% |
| Cellectis S.A. | 333.99 Million USD | 91.633% |